RENAL OSTEODYSTROPHY
1. In Memoriam – A tribute to Professor Jack W. Coburn
Fernando Carrera
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 5
Download
2. Foreword: Why a new supplement on renal osteodystrophy?
Fernando Carrera
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 7
Download
3. Renal osteodystrophy with special emphasis on secondary hyperparathyroidism.
Ewa Lewin, Jinxing Huan, Klaus Olgaard
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 9-18
Download
4. Pathogenesis of secondary hyperparathyroidism and parathyroid hyperplasia.
Eduardo Slatopolsky, Alex J. Brown, Adriana Dusso
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 19-29
Download
5. The different effects of high phosphate levels in chronic kidney disease.
Antonio Canalejo, Yolanda Almadén, Mariano Rodríguez
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 31-40
Download
6. The impact of cardiovascular calcifications in chronic kidney disease: novel pathomechanistic insights.
Markus Ketteler, Ralf Westenfeld, Vincent Brandenburg
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 41-49
Download
7. Vascular calcification, cardiovascular risk and arterial stiffness in haemodialysis patients.
Teresa Adragão
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 51-56
Download
8. Serum markers of bone turnover in the diagnosis of renal osteodystrophy.
Aníbal Ferreira
Rev Port Nefrol Hipert 2005; 19 (4): 241-299
Download
9. Role of vitamin D metabolites in the regulation of PTH synthesis and secretion in chronic kidney disease.
Justin Silver, Iddo Z. Ben Dov
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 73-80
Download
10. Vitamin D analogs for the management of secondary hyperparathyroidism.
Kevin J. Martin, Esther A. González
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 81-86
Download
11. Paracalcitol therapy for secondary hyperparathyroidism.
Myles Wolf, Ravi Thadhani
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 87-96
Download
12. Why target the parathyroid calcium-sensing receptor for the treatment of secondary hyperparathyroidism?
Pablo Ureña Torres, Dominique Prié, Laurent Beck, Gérard Friedlander
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 97-108
Download
13. How are calcimimetics influencing our management of uraemic hyperparathyroidism?
Simon J. Steddon, John Cunningham
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 109-115
Download
14. Sevelamer Hydrochloride: A new Approach to Hyperphosphatemia and Beneficial Effects Beyond Phosphate Control
João M. Frazão, Patrícia Martins, Carla Santos-Araújo
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 117-124
Download
15. Lanthanum carbonate: a new potent non-calcaemic phosphate binder.
Fouad Albaaj, Alastair J. Hutchison
Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 125-133
Download
